Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
Martina Čalušić, Robert Marčec, Lea Luksa, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 5, pp. 2065-2073
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
Wen Wen, Chen Chen, Jiake Tang, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 516-523
Open Access | Times Cited: 394
Mechanisms of action of fluvoxamine for COVID-19: a historical review
Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto
Molecular Psychiatry (2022) Vol. 27, Iss. 4, pp. 1898-1907
Open Access | Times Cited: 107
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
Nur Zawanah Zabidi, Hern Liang Liew, Isra Ahmad Farouk, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 944-944
Open Access | Times Cited: 59
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis
Jiawen Deng, Daniel Rayner, Harikrishnaa Ba Ramaraju, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 5, pp. 578-586
Open Access | Times Cited: 23
Sigma-1 Receptor Signaling: In Search of New Therapeutic Alternatives for Cardiovascular and Renal Diseases
Francisco Javier Munguía-Galaviz, Alejandra Guillermina Miranda‐Díaz, Miguel Alejandro Cardenas-Sosa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 1997-1997
Open Access | Times Cited: 21
Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study
Nicolas Hoertel, Marina Sánchez‐Rico, Erich Gulbins, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 31
Overview of the potential use of fluvoxamine for COVID-19 and long COVID
Kenji Hashimoto
Discover Mental Health (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 20
In silico Evaluation of Bisphosphonates Identifies Leading candidates for SARS-CoV-2 RdRp inhibition
Muzaffar-Ur-Rehman Mohammed, Kishor Suryakant Chougule, Ala Chandu, et al.
Journal of Molecular Graphics and Modelling (2025) Vol. 136, pp. 108939-108939
Closed Access
Sigma-1 Receptor Specific Biological Functions, Protective Role, and Therapeutic Potential in Cardiovascular Diseases
Ahmed Al‐Maamari, Marwa Sultan, Tao Zhang, et al.
Cardiovascular Toxicology (2025)
Closed Access
The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis
Hosein Nakhaee, Moein Zangiabadian, R. Bayati, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0267423-e0267423
Open Access | Times Cited: 26
Antidepressants for COVID-19: A systematic review
Wei Zheng, Heli Sun, Hong Cai, et al.
Journal of Affective Disorders (2022) Vol. 307, pp. 108-114
Open Access | Times Cited: 23
Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19
Nicolas Hoertel, Marina Sánchez‐Rico, Johannes Kornhuber, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 19, pp. 5882-5882
Open Access | Times Cited: 23
COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review
Udo Bonnet, Georg Juckel
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 3, pp. 284-292
Open Access | Times Cited: 22
Association of severe mental illness and septic shock case fatality rate in patients admitted to the intensive care unit: A national population-based cohort study
Inès Lakbar, Marc Léone, Vanessa Pauly, et al.
PLoS Medicine (2023) Vol. 20, Iss. 3, pp. e1004202-e1004202
Open Access | Times Cited: 12
Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study
Irene Visos‐Varela, Maruxa Zapata‐Cachafeiro, María Piñeiro‐Lamas, et al.
European Neuropsychopharmacology (2023) Vol. 71, pp. 96-108
Open Access | Times Cited: 12
Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model
David Péricat, Stephen Adonai Leon‐Icaza, Marina Sánchez‐Rico, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13623-13623
Open Access | Times Cited: 21
Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study
Bruce Kirenga, Levicatus Mugenyi, Marina Sánchez‐Rico, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 12, pp. 5411-5418
Open Access | Times Cited: 11
COVID-19 mortality among selective serotonin reuptake inhibitor users—results from a nationwide cohort
Marius Ahm Stauning, Dogukan Jesper Gür, Christian Torp‐Pedersen, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 8, pp. 1075-1082
Open Access | Times Cited: 11
Molecular Simulation of the Effect of Electron Donor/Acceptor Groups on Fluvoxamine/Serotonin Interactions as a Strategy for COVID‐19 Mitigation
Hamid Hadi, Hitler Louis, Komeil Jafari, et al.
ChemistrySelect (2023) Vol. 8, Iss. 42
Closed Access | Times Cited: 11
A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications
Mani Iyer Prasanth, Dhammika Leshan Wannigama, Angela M. Reiersen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use
Vitória Segabinazzi Foletto, Taciéli F. da Rosa, Marissa Bolson Serafin, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 10, pp. 1601-1611
Open Access | Times Cited: 15
SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants
Almu’atasim Khamees, Jamal Bani-Issa, Mazhar Salim Al Zoubi, et al.
Pathogens (2022) Vol. 11, Iss. 2, pp. 275-275
Open Access | Times Cited: 14
Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis
Huzaifa Ahmad Cheema, Uzair Jafar, Asmaa Ahmed Elrashedy, et al.
Journal of Infection (2022) Vol. 85, Iss. 6, pp. 702-769
Open Access | Times Cited: 14
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
Dylan M. Johnson, Trevor Brasel, Shane Massey, et al.
Antiviral Research (2022) Vol. 209, pp. 105492-105492
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top